Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagus.

Korst RJ, Santana-Joseph S, Rutledge JR, Antler A, Bethala V, DeLillo A, Kutner D, Lee BE, Pazwash H, Pittman RH, Rahmin M, Rubinoff M.

J Thorac Cardiovasc Surg. 2013 Jun;145(6):1529-34. doi: 10.1016/j.jtcvs.2012.11.016. Epub 2012 Dec 6.

2.

Recurrent disease following endoscopic ablation of Barrett's high-grade dysplasia with spray cryotherapy.

Halsey KD, Chang JW, Waldt A, Greenwald BD.

Endoscopy. 2011 Oct;43(10):844-8. doi: 10.1055/s-0030-1256649. Epub 2011 Aug 8.

PMID:
21826629
3.

A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).

Sharma VK, Kim HJ, Das A, Dean P, DePetris G, Fleischer DE.

Endoscopy. 2008 May;40(5):380-7. doi: 10.1055/s-2007-995587.

PMID:
18459074
4.

Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.

Wani S, Rubenstein JH, Vieth M, Bergman J.

Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1. Review.

PMID:
27702561
5.

Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.

Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, Chen X, Madanick RD, Pasricha S, Shaheen NJ.

Am J Gastroenterol. 2013 Feb;108(2):187-95; quiz 196. doi: 10.1038/ajg.2012.413. Epub 2012 Dec 18.

6.

Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett's esophagus: a single-center, phase II clinical trial.

Korst RJ, Santana-Joseph S, Rutledge JR, Antler A, Bethala V, DeLillo A, Kutner D, Lee BE, Pazwash H, Pittman RH, Rahmin M, Rubinoff M.

J Thorac Cardiovasc Surg. 2011 Nov;142(5):1168-73. doi: 10.1016/j.jtcvs.2011.07.037. Epub 2011 Aug 15.

7.

Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.

Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE.

Am J Gastroenterol. 1997 Nov;92(11):2012-6.

PMID:
9362182
8.

Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia.

Pouw RE, Gondrie JJ, Rygiel AM, Sondermeijer CM, ten Kate FJ, Odze RD, Vieth M, Krishnadath KK, Bergman JJ.

Am J Gastroenterol. 2009 Jun;104(6):1366-73. doi: 10.1038/ajg.2009.88. Epub 2009 Apr 21.

PMID:
19491850
9.

[The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].

Endzinas Z, Mickevicius A, Kiudelis M.

Zentralbl Chir. 2004 Apr;129(2):99-103. German.

PMID:
15106039
10.

Detection of intestinal metaplasia after successful eradication of Barrett's Esophagus with radiofrequency ablation.

Vaccaro BJ, Gonzalez S, Poneros JM, Stevens PD, Capiak KM, Lightdale CJ, Abrams JA.

Dig Dis Sci. 2011 Jul;56(7):1996-2000. doi: 10.1007/s10620-011-1680-4. Epub 2011 Apr 6.

11.

Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus.

Neuhaus H, Terheggen G, Rutz EM, Vieth M, Schumacher B.

Endoscopy. 2012 Dec;44(12):1105-13. doi: 10.1055/s-0032-1310155. Epub 2012 Sep 11.

PMID:
22968641
12.

Predictors of recurrent specialized intestinal metaplasia after complete laser ablation.

Fisher RS, Bromer MQ, Thomas RM, Cohen S, Krevsky B, Horwitz B, Glazier KD, Das K, Das KM.

Am J Gastroenterol. 2003 Sep;98(9):1945-51.

PMID:
14499770
13.

Radiofrequency ablation for Barrett's esophagus and low-grade dysplasia in combination with an antireflux procedure: a new paradigm.

dos Santos RS, Bizekis C, Ebright M, DeSimone M, Daly BD, Fernando HC.

J Thorac Cardiovasc Surg. 2010 Mar;139(3):713-6. doi: 10.1016/j.jtcvs.2009.10.032. Epub 2010 Jan 13.

14.

Radiofrequency ablation in Barrett's esophagus with dysplasia.

Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ.

N Engl J Med. 2009 May 28;360(22):2277-88. doi: 10.1056/NEJMoa0808145.

15.

Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett's esophagus.

Lee JK, Cameron RG, Binmoeller KF, Shah JN, Shergill A, Garcia-Kennedy R, Bhat YM.

Endoscopy. 2013 Jul;45(7):571-4. doi: 10.1055/s-0032-1326419. Epub 2013 Apr 16.

PMID:
23592390
16.

Squamous islands in Barrett's esophagus: what lies underneath?

Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE.

Am J Gastroenterol. 1998 Mar;93(3):332-5.

PMID:
9517634
17.

Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.

Chennat J, Ross AS, Konda VJ, Lin S, Noffsinger A, Hart J, Waxman I.

Gastrointest Endosc. 2009 Sep;70(3):417-21. doi: 10.1016/j.gie.2009.01.047. Epub 2009 Jun 24.

PMID:
19555948
18.

Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.

Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, Lin S, Ferguson MK, Posner MC, Waxman I.

Am J Gastroenterol. 2009 Nov;104(11):2684-92. doi: 10.1038/ajg.2009.465. Epub 2009 Aug 18.

PMID:
19690526
19.

Subsquamous intestinal metaplasia after ablation of Barrett's esophagus: frequency and importance.

Mashimo H.

Curr Opin Gastroenterol. 2013 Jul;29(4):454-9. doi: 10.1097/MOG.0b013e3283622796. Review.

PMID:
23674187
20.

Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication.

Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG.

Gastrointest Endosc. 2013 Feb;77(2):190-9. doi: 10.1016/j.gie.2012.10.013.

PMID:
23317687

Supplemental Content

Support Center